Ninety One UK Ltd Sells 64,875 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Ninety One UK Ltd has reduced its stake in Edwards Lifesciences by 0.9%, selling 64,875 shares, while still owning approximately 6.94 million shares valued at $542.74 million.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding estimates, with revenue increasing by 11.9% to $1.53 billion compared to the previous year.
• Research analysts have upgraded their price targets for Edwards Lifesciences, with Royal Bank of Canada setting a new target of $89.00 and Barclays raising theirs to $95.00.

Ninety One UK Ltd trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 0.9% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,939,542 shares of the medical research company's stock after selling 64,875 shares during the period. Edwards Lifesciences makes up approximately 1.3% of Ninety One UK Ltd's holdings, making the stock its 23rd biggest holding. Ninety One UK Ltd owned approximately 1.18% of Edwards Lifesciences worth $542,741,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. LBP AM SA bought a new position in Edwards Lifesciences during the second quarter valued at $1,337,000. Cooper Financial Group purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at about $373,000. Truist Financial Corp lifted its holdings in shares of Edwards Lifesciences by 5.5% in the 2nd quarter. Truist Financial Corp now owns 49,006 shares of the medical research company's stock valued at $3,833,000 after acquiring an additional 2,555 shares during the last quarter. HB Wealth Management LLC grew its position in Edwards Lifesciences by 9.2% in the second quarter. HB Wealth Management LLC now owns 23,544 shares of the medical research company's stock worth $1,841,000 after acquiring an additional 1,982 shares in the last quarter. Finally, GC Wealth Management RIA LLC purchased a new position in Edwards Lifesciences in the second quarter worth about $304,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Up 0.8%

Shares of EW opened at $77.84 on Wednesday. The firm has a fifty day moving average price of $78.54 and a 200-day moving average price of $75.84. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $45.70 billion, a P/E ratio of 11.20, a P/E/G ratio of 3.71 and a beta of 1.07. Edwards Lifesciences Corporation has a 12-month low of $64.00 and a 12-month high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm's revenue was up 11.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Morgan Stanley increased their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a "buy" rating in a research note on Monday, September 22nd. Barclays boosted their price objective on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research report on Friday, July 25th. Finally, William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $86.61.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.